FocalTherics™ to Participate in Upcoming Investor Conferences
FocalTherics (Nasdaq: FOCL) will participate in upcoming investor conferences, starting with the UBS Global Healthcare Conference on November 10, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
FocalTherics (Nasdaq: FOCL) will participate in upcoming investor conferences, starting with the UBS Global Healthcare Conference on November 10, 2026.
Management is scheduled for a UBS fireside chat at 1:15 pm ET, one-on-one meetings at the Jefferies Global Healthcare Conference in London on November 18, and a Piper Sandler 38th Annual Healthcare Conference fireside chat on December 2 at 4:00 pm ET.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FocalTherics™ to Participate in Upcoming Investor Conferences
AUSTIN, Texas, Nov. 04, 2026 (GLOBE NEWSWIRE) -- FocalTherics (Nasdaq: FOCL) (the “Company”), a global leader in robotic focal therapy, today announced that the Company will participate in the following investor conferences:
- UBS Global Healthcare Conference. Management is scheduled to participate in a Fireside Chat on November 10th, 2026, at 1:15 pm ET. Interested parties can access the live and archived webcast on the News/Events page of the Investors section of FocalTherics’ website at www.focalone.com.
- Jefferies Global Healthcare Conference in London. Management will host 1x1 meetings on November 18th, 2026.
- Piper Sandler 38th Annual Healthcare Conference. Management is scheduled to participate in a Fireside Chat on December 2nd, 2026, at 4:00 pm ET. Interested parties can access the live and archived webcast on the News/Events page of the Investors section of FocalTherics’ website at www.focalone.com.
About FocalTherics
A recognized leader in robotic focal therapy, FocalTherics develops, manufactures, and markets minimally invasive medical devices worldwide to treat various conditions using proprietary focused ultrasound technology. The Company’s flagship platform, Focal One® Robotic HIFU, combines advanced imaging, real-time treatment planning, robotic precision, and HIFU technology to deliver personalized focal therapy designed to optimize clinical outcomes while preserving quality of life.
Investor Contacts
Louisa Smith
Gilmartin Group
investor.relations@focalone.com
